What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials-Reference-Cited by-同舟云学术

What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials

Published:2014-04 Issue:4 Volume:101 Page:E19-E24
ISSN:0007-4551
Container-title:Bulletin du Cancer
language:fr
Short-container-title:Bulletin du Cancer

Author:

Penel Nicolas,Ryckewaert Thomas,Kramar Andrew

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Reference13 articles.

1. Management of “unfavourable” carcinoma of unknown primary site: synthesis of recent literature;Penel;Crit Rev Oncol Hematol,2012

2. ESMO Guidelines Working Group. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Fizazi;Ann Oncol,2011

3. Design issues of randomized phase II trials and a proposal for phase II screening trials;Rubinstein;J Clin Oncol,2005

4. New designs for the selection of treatments to be tested in randomized clinical trials;Simon;Stat Med,1994

5. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint;Mick;Control Clin Trials,2000

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework;Health Technology Assessment;2021-12

2. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer;British Journal of Cancer;2020-09-11